Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant

The role of allogeneic hematopoietic cell transplant (allo-HCT) as consolidation after initial venetoclax therapy and the efficacy of venetoclax salvage therapy for relapse after allo-HCT in patients with acute myeloid leukemia (AML) are unclear. We conducted a retrospective study of patients with A...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia & lymphoma 2021-12, Vol.62 (14), p.3394-3401
Main Authors: Bewersdorf, Jan Philipp, Derkach, Andriy, Gowda, Lohith, Menghrajani, Kamal, DeWolf, Susan, Ruiz, Josel D., Ponce, Doris M., Shaffer, Brian C., Tamari, Roni, Young, James W., Jakubowski, Ann A., Gyurkocza, Boglarka, Chan, Alexander, Xiao, Wenbin, Glass, Jacob, King, Amber C., Cai, Sheng F., Daniyan, Anthony, Famulare, Christopher, Cuello, Bernadette M., Podoltsev, Nikolai A., Roshal, Mikhail, Giralt, Sergio, Perales, Miguel-Angel, Seropian, Stuart, Cho, Christina, Zeidan, Amer M., Prebet, Thomas, Stein, Eytan M., Tallman, Martin S., Goldberg, Aaron D., Stahl, Maximilian
Format: Article
Language:English
Subjects:
Acute myeloid leukemia
AML
Bridged Bicyclo Compounds, Heterocyclic - therapeutic use
Hematopoietic Stem Cell Transplantation - adverse effects
Hematopoietic Stem Cell Transplantation - methods
Humans
Leukemia, Myeloid, Acute - diagnosis
Leukemia, Myeloid, Acute - therapy
MDS
Retrospective Studies
Sulfonamides
transplant
venetoclax
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The role of allogeneic hematopoietic cell transplant (allo-HCT) as consolidation after initial venetoclax therapy and the efficacy of venetoclax salvage therapy for relapse after allo-HCT in patients with acute myeloid leukemia (AML) are unclear. We conducted a retrospective study of patients with AML or myelodysplastic syndrome (MDS) who received venetoclax either before or after allo-HCT at Memorial Sloan Kettering Cancer Center and Yale University from 11 August 2016 to 16 November 2020. Among 39 heavily pretreated patients who received venetoclax before allo-HCT, median OS from allo-HCT was not reached after a median follow up of 12.5 months resulting in a 12-month OS estimate of 79.0%. In 37 patients who had received venetoclax-based combinations as salvage therapy after allo-HCT, the overall response rate was 32% with a median OS of 4.7 months (12-month OS estimate: 43.4%). Four patients underwent a second allo-HCT following venetoclax-based salvage therapy suggesting it as a potential salvage treatment option.
ISSN:1042-8194
1029-2403
DOI:10.1080/10428194.2021.1966788